Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05545059
Other study ID # 2020-KY-126
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 24, 2022
Est. completion date March 31, 2023

Study information

Verified date November 2021
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Dengfeng Geng, Dr.
Phone 020-81332623
Email dr.dfengg@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Resistant hypertension (RH) accounted for a considerable proportion of patients with hypertension. It has been revealed to impose certain adverse effects on the prognosis of patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan being fully confirmed in previous studies, there were no related randomized controlled trials (RCT) about this potency among Chinese patients with RH. The investigators designed this study to evaluated effects and safety of sacubitril/valsartan versus valsartan on Chinese patients with RH.


Description:

Background Resistant hypertension (RH) accounted for a considerable proportion of patients with hypertension. It has been revealed to impose certain adverse effects on the prognosis of patients with cardiovascular diseases. The antihypertensive effect of sacubitril/valsartan being fully confirmed in previous studies, there were no related randomized controlled trials (RCT) about this potency among Chinese patients with RH. Purpose Describing the design of the Effects of Sacubitril/valsartan Versus Valsartan on Refractory Hypertension (EOSORH) trial. Methods and analysis This is a monocentric, randomized, parallel-group, controlled trial which will investigate the efficacy and safety of sacubitril/valsartan in the treatment of Chinese patients with RH. A total of 138 patients will be enrolled who are diagnosed with RH according to the Guidelines for Prevention and Treatment of Hypertension in China (2018 revision). After a washout period, subjects will be randomized to sacubitril/valsartan group or valsartan group in a 1:1 ratio. The primary outcome is the change in 24 hours average ambulatory systolic blood pressure (SBP) from baseline to 8 weeks after randomization, comparing the sacubitril/valsartan group with valsartan group. The secondary outcomes including change in 24 hours average ambulatory diastolic blood pressure (DBP), clinic blood pressure and series of cardiac and renal hematologic indicators. Safety endpoints will also be evaluated, covered changes in blood potassium level, renal function, hypotension, etc. Full Analysis Set (FAS), per-protocol set (PPS) and safety set (SS) will be defined. Baseline data will be analyzed by using data from FAS whereas the analysis of primary outcome will be based on FAS and PPS but the conclusions of FAS are dominant. Ethics and dissemination The research protocol has been approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. This research is designed to investigate the efficacy and safety of sacubitril/valsartan in Chinese RH patients. Findings will be shared by Sun Yat-sen Memorial Hospital, policymakers and the academic community to promote the clinical pharmacal therapy of RH in China. Discussion The effects of sacubitril/valsartan on hypertension have been widely reported by a series of large RCT in recent years, while its application in RH patients is still elusive. The study will provide a new pharmacal strategy for the treatment of RH.


Recruitment information / eligibility

Status Recruiting
Enrollment 138
Est. completion date March 31, 2023
Est. primary completion date October 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of resistant hypertension - =18 and =75 years old at the time of randomization - Must agree to comply with all requirements and sign the informed consent form Exclusion Criteria: - unwilling to sign informed consent. - Severe renal insufficiency - Research related drug contraindications - secondary hypertension - Cardiovascular event - Persistent arrhythmia, valvular heart disease, and class III-IV heart failure or left ventricular ejection fraction <45%. - Severe liver function impairment (Child-Pugh C), biliary cirrhosis and/or cholestasis - History of angioedema and asthma - Woman of childbearing age who do not take effective contraceptive measures or pregnant or breastfeeding - Allergic to drugs related to the study - Suffering from serious tumor-related diseases, receives tumor-related treatment, or has a life expectancy of less than 2 years - Planning to join other clinical trials - Anticipated changes in medical conditions - Need to take study-related drugs for reasons other than hypertension - Suffering from other diseases that may prevent the patient from participating fully period of the study - Other any concomitant conditions - Must continuously take any drugs that affect the results

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sacubitril/valsartan
In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
valsartan
In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.

Locations

Country Name City State
China Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (5)

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. doi: 10.1161/CIRCULATIONAHA.108.189141. — View Citation

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24. Review. — View Citation

Kario K, Shin J, Chen CH, Buranakitjaroen P, Chia YC, Divinagracia R, Nailes J, Hoshide S, Siddique S, Sison J, Soenarta AA, Sogunuru GP, Tay JC, Teo BW, Turana Y, Zhang Y, Park S, Van Minh H, Wang JG. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: The HOPE Asia Network. J Clin Hypertens (Greenwich). 2019 Sep;21(9):1250-1283. doi: 10.1111/jch.13652. — View Citation

Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014 Apr;63(4):698-705. doi: 10.1161/HYPERTENSIONAHA.113.02002. Epub 2014 Jan 20. — View Citation

Lamirault G, Artifoni M, Daniel M, Barber-Chamoux N, Nantes University Hospital Working Group On Hypertension. Resistant Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):61-72. doi: 10.2174/1573402115666191011111402. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary the change in 24 hours average ambulatory systolic pressure from baseline to 8 weeks after randomization the change in 24 hours average ambulatory systolic blood pressure (in mmHg) from baseline to 8 weeks after randomization 8 weeks after randomization
Secondary Change in 24 hours average ambulatory diastolic blood pressure, daytime and night-time blood pressure and office blood pressure Change in 24 hours average ambulatory diastolic blood pressure, daytime systolic blood pressure, night-time systolic blood pressure, daytime diastolic blood pressure, night-time diastolic blood pressure, office systolic blood pressure and office diastolic blood pressure 8 weeks after randomization
Secondary Change in level of cardiac marker reflecting the heart failure serum N-terminal pro-brain natriuretic peptide (NT-proBNP in pg/ml) 8 weeks after randomization
Secondary Change in level of cardiac marker reflecting myocardial damage cardiac troponin T (cTnT in pg/ml) 8 weeks after randomization
Secondary Change in level of novel cardiac marker reflecting the heart failure suppression of Tumorigenicity 2 (sST2 in ng/ml) 8 weeks after randomization
Secondary Change in level of cardiac marker reflectting myocardial metabolism cyclic guanosine monophosphate (cGMP in pmol/l) 8 weeks after randomization
Secondary Change in level of estimated glomerular filtration rate Change in level of estimated glomerular filtration rate (eGFR in mL/min/1.73m^2). 8 weeks after randomization
Secondary Change in level of urinary albumin to creatinine ratio Change in level of urinary albumin to creatinine ratio (in mg/mmol). 8 weeks after randomization
Secondary the control rate of blood pressure The control rate of blood pressure. Blood pressure control was defined as a blood pressure of less than 140/90 mmHg after medical treatment. 8 weeks after randomization
Secondary Change in left atrium diameter determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in left atrium diameter (LA in mm) determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in left ventricular mass index determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in left ventricular mass index (LVMI in g/m^2) determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in left ventricular end diastolic volume index determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in left ventricular end diastolic volume index (LVEDVI in ml/m^2) determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in left ventricular end systolic volume index determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in left ventricular end systolic volume index (LVESVI in ml/m^2) determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in left ventricular ejection fraction determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in left ventricular ejection fraction (LVEF in %) determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in E/A determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in E/A determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging.The E/A ratio is an echocardiographic index that reflects the diastolic function of the heart Under normal circumstances, E/A > 1. 8 weeks after randomization
Secondary Change in E/e' determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in E/e' determined by ultrasonic cardiogram and three-dimensional .The E/E' ratio is of great clinical significance in determining the diastolic function of the heart. If the E/E' ratio is <8, diastolic dysfunction can generally be ruled out. If the E/E' ratio is > 15, it generally indicates the existence of diastolic dysfunction. 8 weeks after randomization
Secondary Change in left ventricular overall longitudinal peak strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in left ventricular overall longitudinal peak strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in overall radial peak strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in overall radial peak strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in overall circumstantial peak strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in overall circumstantial peak strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
Secondary Change in area strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging Change in area strain determined by ultrasonic cardiogram and three-dimensional speckle tracking imaging. 8 weeks after randomization
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05426707 - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension N/A
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Active, not recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Terminated NCT02295683 - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4
Recruiting NCT04637152 - Sacubitril/Valsartan in Resistant Hypertension Phase 2